Patient knowledge about biosimilars and satisfaction with the education provided by rheumatologists or nurse specialists in a biosimilar multiswitch scenario – The perception study

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

(2022) Hillel P. Cohen et al.   BIODRUGS

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Delegation ärztlicher Leistungen in der Rheumatologie

(2020) A. Krause et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Patients’ beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch

(2020) Chiara Gasteiger et al.   RHEUMATOLOGY INTERNATIONAL

Ist eine Delegation ärztlicher Leistungen auf rheumatologische Fachassistenten bei der Evaluierung von Patienten mit Verdacht auf ankylosierende Spondylitis möglich? – Ergebnisse der PredAS-Studie

(2020) U. Kiltz et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence

(2020) Brian G. Feagan et al.   ADVANCES IN THERAPY

Educational inequalities in mortality associated with rheumatoid arthritis and other musculoskeletal disorders in Sweden

(2019) Aliasghar A. Kiadaliri et al.   BMC MUSCULOSKELETAL DISORDERS

2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis

(2019) Bianca Bech et al.   ANNALS OF THE RHEUMATIC DISEASES

The effects of message framing on patients’ perceptions and willingness to change to a biosimilar in a hypothetical drug switch

(2019) Chiara Gasteiger et al.   ARTHRITIS CARE & RESEARCH

2019 EULAR recommendations for the generic core competences of health professionals in rheumatology

(2019) Lisa Edelaar et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis

(2019) Christopher J. Edwards et al.   CLINICAL RHEUMATOLOGY

Patient satisfaction survey: substitution of reference etanercept with a biosimilar product

(2019) Cristina Martínez-Múgica Barbosa et al.   European Journal of Hospital Pharmacy-Science and Practice

Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow-up survey

(2019) Laurent Peyrin-Biroulet et al.   United European Gastroenterology Journal

Biosimilars und der Nocebo-Effekt

(2019) J. Braun et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France

(2018) Jérôme Avouac et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

(2018) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect

(2018) Vincent Germain et al.   ANNALS OF THE RHEUMATIC DISEASES

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

(2018) Bente Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

(2016) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR-Empfehlungen für die Schulung von Patienten mit entzündlich-rheumatischen Gelenkerkrankungen

(2016) J. Patermann et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Effects of needs-based patient education on self-efficacy and health outcomes in people with rheumatoid arthritis: a multicentre, single blind, randomised controlled trial

(2015) M Ndosi et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

(2015) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

The outcome and cost-effectiveness of nurse-led care in people with rheumatoid arthritis: a multicentre randomised controlled trial

(2013) Mwidimi Ndosi et al.   ANNALS OF THE RHEUMATIC DISEASES

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

(2010) P. Machado et al.   ANNALS OF THE RHEUMATIC DISEASES